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Background: To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin
radiation therapy and concurrent temozolomide. We hypothesize that patients treated with margins in accordance with
Adult Brain Tumor Consortium guidelines (ABTC) will demonstrate patterns of failure consistent with previous
series of patients treated with 2–3 cm margins.
Methods: A retrospective review was performed of patients treated at the University of Alabama at Birmingham
for GBM between 2000 and 2011. Ninety-five patients with biopsy-proven disease and documented disease
progression after treatment were analyzed. The initial planning target volume includes the T1-enhancing tumor
and surrounding edema plus a 1 cm margin. The boost planning target volume includes the T1-enhancing tumor
plus a 1 cm margin. The tumors were classified as in-field, marginal, or distant if greater than 80%, 20-80%, or less than
20% of the recurrent volume fell within the 95% isodose line, respectively.
Results: The median progression-free survival from the time of diagnosis to documented failure was 8 months
(range 3–46). Of the 95 documented recurrences, 77 patients (81%) had an in-field component of treatment
failure, 6 (6%) had a marginal component, and 27 (28%) had a distant component. Sixty-three patients (66%)
demonstrated in-field only recurrence.
Conclusions: The low rate of marginal recurrence suggests that wider margins would have little impact on the
pattern of failure, validating the use of limited margins in accordance ABTC guidelines.
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More than one-third of the approximately 67,000 cases
of primary brain and other nervous system tumors diag-
nosed each year in U.S. adults are malignant. GBM is
the most common malignant histology and represents a
disproportionate cause of cancer morbidity and mortal-
ity, even though primary brain tumors account for only
2 percent of all cancers [1]. Despite significant therapeutic
advances in recent years, the prognosis of GBM remains
dismal, with few patients surviving beyond 5 years. The
addition of temozolomide resulted in an improvement in
median survival from 12.1 to 14.6 months [2].* Correspondence: jfiveash@uab.edu
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unless otherwise stated.Studies comparing whole-brain with partial-brain irradi-
ation showed no benefit from whole-brain irradiation, lead-
ing to the current practice of partial-brain treatment [3].
Autopsy series have shown that the pattern of failure of
GBM after radiation therapy is predominantly within 2- to
3-cm of the primary tumor bed, which has led to the adop-
tion of 2- to 3-cm radiation margins in conventional proto-
cols [4-6]. The volume of irradiated brain is associated with
the development of neurotoxicity [7,8]; therefore reducing
the treatment volume may ameliorate these side effects.
The margins defined by the ABTC are smaller than those
utilized in protocols from the Radiation Therapy Oncology
Group (RTOG) and European Organization for Research
and Treatment of Cancer (EORTC). We hypothesize that
patients treated in accordance with ABTC guidelines willral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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series of patients treated with 2–3 cm margins.
Materials and methods
Selection of patients
This retrospective study was approved by the University
of Alabama at Birmingham (UAB) Institutional Review
Board. The records of all patients treated for GBM at
UAB between April 2000 and November 2011 were retro-
spectively assessed. This review included only patients
with biopsy-proven GBM who suffered documented dis-
ease progression following treatment with radiation ther-
apy and concurrent temozolomide. Adequate imaging
prior to treatment, radiation dosimetry records, and radio-
graphic assessment at failure were available for all patients
included in this review.
Treatment
All patients were treated at UAB according to the ABTC
guidelines for radiation oncology. The most recent
version of these guidelines is shown in Table 1. The pre-
scribed dose varied minimally and generally was 46 Gy
to an initial gross tumor volume (GTV) encompassing
the primary tumor and surrounding edema on post-
operative T2 or FLAIR MRI. This was expanded by
5 mm and then edited to conform to anatomic barriers
to tumor spread in order to create the initial clinical
target volume (CTV). The CTV was expanded an add-
itional 5 mm to generate the initial planning target vol-
ume (PTV). The boost GTV was defined as the residual
T1 contrast-enhancing tumor plus resection cavity and
was expanded in similar fashion. The boost PTV was
prescribed an additional 14 Gy, and the total dose to the
boost volume was 60 Gy delivered in daily fractions of
2 Gy. The dose-reference point was the International
Commission on Radiation Units (ICRU) reference point,
usually the isocenter located in the center of the boost
volume. Radiotherapy plans were normalized so the 95%
isodose line encompassed the PTV completely.
Patients were followed with serial MRI scans at 1 month
post-radiation and then at 2-month intervals. Typical
imaging sequences included pre- and post-contrast T1,
T2, and FLAIR. Newer techniques including perfusion,Table 1 ABTC guidelines for target definition
Target volume Definition
GTV1 T1 enhancing and non-enhancing tumor volume
(T2 or FLAIR)
GTV2 T1 enhancing tumor volume
CTV1;2 GTV plus a margin of 5 mm
PTV1;2 CTV plus a margin of 3–5 mm
Note: GTV volume is based on postoperative day 0–1 MRI. GTV, Gross Tumor
Volume; CTV, Clinical Target Volume; PTV, planning target volume; ABTC, Adult
Brain Tumors Consortium.diffusion, and MR spectroscopy were used in follow-up of
many patients beginning in 2005. Because of the possibility
of post-radiation imaging changes or pseudo-progression,
an imaging or clinical change developing after radiation in
the absence of recurrent tumor, changes at the first follow-
up scan were managed conservatively with observation or a
trial of steroids. Patients outside of this time frame or re-
fractory to steroid therapy were generally considered to
have progressive disease, and additional treatment was at
the discretion of the treating physician.
Analysis
The determination of disease progression was made by
the treating physician with the help of the UAB Central
Nervous System (CNS) multidisciplinary tumor board
based upon clinical and radiographic changes. MRI scans
documenting failure after concurrent temozolomide and
radiation were fused to the original treatment planning
CT scans electronically using the ECLIPSE treatment
planning system (Varian Medical Systems, Palo Alto,
CA, USA). In order to reduce bias, the recurrent tumor
volumes were generated by contouring the contrast-
enhancing abnormalities on the MRIs prior to fusion
with the isodose curves of the treatment plan. The re-
current tumors were analyzed to determine the volume
of recurrent tumor present within the 95% isodose line
of the boost plan of the completed treatment. The recur-
rent tumors were classified as “in-field” if >80% of the
T1-enhancing tumor volume was covered by the 95%
isodose line, “marginal” if >20 but ≤80% of the tumor
volume was within the 95% isodose line, or distant in
<20% of the tumor volume was located within the 95%
isodose line. In cases of multiple discrete sites of failure,
each lesion was independently analyzed relative to the
95% isodose line. Follow-up time was calculated from
the date of pathological diagnosis of GBM until the most
recent follow-up visit with imaging.
Statistics
The Kaplan-Meier method was used to estimate the
rates of time to progression. Associations of patient
factors with time to progression were assessed with the
log-rank test. Statistical significance was determined at




Ninety-five cases of recurrent GBM initially treated with
concurrent temozolomide and radiation therapy between
April 2000 and November 2011 with adequate imaging
at time of failure and sufficient data for reconstruction
of radiation dose distributions were identified and in-
cluded in the analysis. Of the 90 patients for which
















60 Gy 92 97%
<60 Gy 3 3%
Adjuvant TMZ
Concurrent TMZ 95 100%
Received post-RT TMZ 83 87%
Did not receive post-RT TMZ 12 13%
Median cycles 6
Range of cycles 0-26
Abbreviations: GTR Gross tumor resection, STR sub-total resection,
TMZ temozolomide.
Figure 1 Patterns of Failure.
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gone a gross total resection, 50 patients (56%) had under-
gone a subtotal resection, and 13 patients (14%) had only
been biopsied.
Ninety-two of the 95 patients received 60 Gy in 30
fractions, 1 patient received 59.4 Gy in 33 fractions, and
2 patients received 56 Gy in 28 fractions. In all cases, pa-
tients received daily temozolomide at 75 mg/m2 concur-
rent with radiation. Additional temozolomide was given
adjuvantly in 83 of 95 patients, delivered at a dose of
150–200 mg/m2 on each of the first 5 days of every 28-
day cycle. Patients received a median of 6 (range, 0–26)
cycles of adjuvant temozolomide. Patient and treatment
characteristics are summarized in Table 2.
Twenty-eight patients (29%) were treated as part of an
ABTC clinical trial and received additional trial drugs.
Thirteen patients received Cilengitide, 9 patients received
ABT-510, 2 patients received AT-101, and 4 patients were
treated with hydroxychloroquine.
Outcomes
The median time from completion of radiation to recur-
rence documented by MRI was 8 months (range, 3–46).
The median volume of recurrent disease was 19.08 mL
(range 0.11-234.11). The association between time to re-
currence and location of failure was assessed. For the
purpose of this analysis, sites of treatment failure were
categorized into those containing no distant component
of recurrence (i.e. in-field or marginal failure only) and
those containing a distant component of recurrence.
There was no association between time to recurrence
and location of failure (p = 0.508). There was also no as-
sociation found between type of resection (p = 0.285), or
presence of multifocal disease (p = 0.233) and time to
recurrence.
The patterns of failure relative to the treated volumes
are summarized in Figure 1. Of the 95 documented re-
currences, 77 patients (81%) had an in-field component
of treatment failure, 6 (6%) had a marginal component,
and 27 (28%) had a distant component. Sixty-three pa-
tients (66%) demonstrated in-field only recurrence.
Three (3%) failures were marginal only, 14 (15%) were
distant only, 2 (2%) were in-field and marginal, 12 (13%)
were in-field and distant, and 1 (1%) was marginal and
distant. Of the 27 patients with a distant component of
failure, 4 patients (15%) originally had multifocal disease.
There was no association between pattern of failure and
extent of resection or multifocal disease. Examples of
distant and marginal failures are shown in Figures 2 and
3, respectively.
Discussion
Our institution has previously reported our experience
treating 20 patients with standard doses of radiation
Figure 3 Example of marginal failure: 1. sites of failure. 2. 95%
isodose line of boost dose.
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temozolomide from April 2000 to June 2005 [9]. The
present analysis combines this data with those of an
additional 75 patients treated from 2005 to November
2011. We found that the predominant pattern of failure
was within the treatment volume, as 81% of patients had
an in-field component to their disease progression. Six
percent of patients had a marginal component to disease
progression, and 28% had a site of failure distant to the
treatment field. No factors were found to be associated with
the pattern of failure or time to disease progression.
Autopsy studies have shown that glioblastoma patients
treated with radiotherapy fail within 2- to 3-cm of the
primary tumor bed, which has led to the use of analo-
gous treatment margins. Several institutions have exam-
ined the pattern of failure following radiation therapy
using conformal techniques with 2- to 3-cm margins
and found that the pattern of failure remains predomin-
antly within the treatment field [10-13].
A number of studies have looked at patients treated
with radiation therapy prior to the introduction of
temozolomide and found that the pattern of failure is
predominantly local. A study by Lee reported failures
among 36 patients treated with radiation alone to 70–
80 Gy at the University of Michigan using 3D-conformal
technique, and found that 89% of patients experienced
failures within the treatment field. A follow-up publica-
tion by Chan examined an additional 34 patients treated
with radiation alone. Despite dose escalation to 90 Gy,Figure 2 Example of local and distant failure: 1. sites of failure. 2.
95% isodose line of boost dose.91% still failed within the treatment field. All other pa-
tients experienced marginal failures, and no distant fail-
ures were observed in this series.
Another study of the patterns of failure of GBM after
radiation and concurrent temozolomide was published
by Brandes et al. [14]. In this study, 95 patients were
treated with radiation, concurrent and adjuvant temo-
zolomide. The patients received 60 Gy delivered to the
T1 and T2 lesions on MRI with a 2- to 3-cm margin
for the CTV with no field reduction during treatment.
Despite using considerably larger target volumes than
the present study, Brandes reported 21.5% of recur-
rences outside the radiation field, and 6.3% of recur-
rences at the margin of the radiation field. This study
also found that 06-methylguanine DNA methyltrans-
ferase (MGMT) status was associated with the pattern
of recurrence. Eighty-five percent of patients with
unmethylated MGMT failed in-field or at the margin,
compared with 57.9% of patients with methylated
MGMT. Recurrences outside of the RT field occurred
at a significantly longer time interval than those within
the treatment field.
Glioblastoma research protocols typically employ radi-
ation margins according to RTOG or EORTC guidelines.
The EORTC uses a single-phase technique in which the
GTV is defined as the surgical tumor bed plus any re-
sidual enhancing tumor. This is expanded by 2–3 cm to
create the CTV and another 0.5-0.7 cm for the PTV.
The GTV in RTOG protocols is similarly defined, but
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This is then expanded 2.0-2.5 cm to create the initial
PTV. This initial volume is treated to 46 Gy in 23 frac-
tions before a cone-down in which the GTV is expanded
by 2.5-3.0 cm without accounting for edema. This final
PTV is then treated with an additional 14 Gy. These guide-
lines are in contrast with ABTC guidelines in which the
GTV is expanded 0.5 cm to create the CTV and another
0.5 cm for the PTV as described above.
Increasing the margin size can substantially increase
the total volume of brain irradiated. Treating a round
tumor with a 5 cm radius using a 1.0 cm total GTV to
PTV margin will result in a total treatment volume of
452 cm3. If this same tumor is treated using a 2.5 or
3.5 cm total margin, then the resulting treatment volume
is increased to 707 or 908 cm3, respectively. In this
example, increasing the margin by 2.5 cm more than
doubles the treatment volume, which would be expected
to increase toxicity to the patient.
In recent years, several institutions have reported their
experiences with limited-margin radiation in adherence
to ABTC guidelines [9,15,16]. Brain irradiation is associ-
ated with neurotoxic side effects including radionecrosis
and cognitive decline [7,8]. The volume of irradiated
brain is believed to be associated with the development
of these complications [17], and treating smaller vol-
umes should theoretically reduce these effects. While
the long-term prognosis of glioblastoma remains dismal
[2], quality of life is an important consideration for pa-
tients treated with radiation.
Emory University published their experience with 43
patients with disease progression after treatment with
concurrent temozolomide and radiation with 0.5 cm
CTV margins [15]. They found that 93% of patients re-
curred within the treatment field, 5% were marginal, and
2% were distant relative to the 60 Gy isodose line. The
researchers further analyzed the patients by creating
hypothetical PTVs for each patient based upon RTOG
guidelines. They found no difference in the distribution
of pattern of failure when the two boost techniques were
compared and concluded that a GTV to PTV margin of
1 cm or less did not appear to increase the risk of mar-
ginal or distant tumor failures.
A large series from Wake Forest examined 161 pa-
tients treated with radiation with 5-, 10, and 15- to 20-
mm CTV margins [16]. Thirty-four patients were treated
with 5-mm margins as in the present study. The re-
searchers classified the patterns of failure as either within
the 60 Gy volume, within the 46 Gy volume, marginal
(within 2 cm from the 46 Gy volume), or distant (beyond
2 cm from the 46 Gy volume). They found no statistical dif-
ference between patients treated with different margins and
the patterns of failure. There was no significant difference
in progression-free survival or overall survival among thedifferent treatment margin groups. Patients who failed
within the 46 Gy volume had improved overall survival
compared with patients who failed within the 60 Gy
volume.
Chang et al. published a series that addressed the ques-
tion of whether or not to include peritumoral edema in
CTV delineation for glioblastoma [18]. They examined 48
patients who received three-dimensional conformal radi-
ation with a 2-cm margin that did not include edema
within the CTV and subsequently experienced disease pro-
gression. They generated hypothetical treatment plans
according to RTOG guidelines that specify inclusion of
peritumoral edema. Ninety percent of patients failed in cen-
tral and in-field localization in either treatment plan. They
found no statistical correlation between the location of re-
current tumor and edema volumes, and the pattern of fail-
ure was identical between the two sets of plans. Patients
with volume of edema >75 cm3 would have 18% of their
brain irradiated to 60 Gy under the RTOG guidelines com-
pared with 7% when peritumoral edema was excluded.
The present study of 95 patients with disease progression
after treatment with radiation therapy and concurrent
temozolomide represents the largest series of patients
treated with 0.5 cm CTV margins (1.0 cm total PTV mar-
gin). Acknowledged limitations of this study include its
retrospective nature with inherent problems of selection
bias. As described above, a subset of 28 patients was treated
as part of an ABTC clinical trial and received additional
trial drugs that may have influenced tumor cell activity and
the patterns of disease progression. Another possible weak-
ness involves the difficulty of distinguishing tumor progres-
sion from pseudoprogression, though we attempted to
minimize the impact of this flaw by considering transient
changes to represent pseudoprogression. The criteria from
the Response Assessment in Neuro-oncology (RANO)
Working Group were eventually adopted to evaluate dis-
ease progression, but the majority of patients were deemed
to have progression prior to their publication. Despite these
weaknesses, the data demonstrate a pattern of marginal
failure consistent with previous studies using larger radi-
ation margins.
Conclusions
The use of limited-margin radiation therapy with con-
current and adjuvant temozolomide in the treatment of
glioblastoma produces patterns of failure consistent with
the existing literature. The low rate of marginal recur-
rence suggests that wider margins would have little
impact on the pattern of failure, validating the use of
limited margins in accordance with Adult Brain Tumor
Consortium guidelines.
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